Výsledky vyhledávání - "Khalil, Nazzal"

Expression of programmed cell death protein 1 and T‐cell immunoglobulin‐ and mucin‐domain‐containing molecule‐3 on peripheral blood CD4+CD8+ double positive T cells in patients with chronic hepatitis C virus infection and in subjects who spontaneously cleared the virus

Autor: Agnieszka Pawełczyk, Sylwia Osuch, Karol Perlejewski, Maciej Janiak, Kamila Caraballo Cortés, Justyna Kaźmierczak, Khalil Nazzal, Tomasz Laskus, Marek Radkowski, Joanna Jabłońska, Iwona Bukowska-Ośko, Hanna Berak, Marcin Paciorek, Anna Stelmaszczyk-Emmel

Publikováno v: Journal of Viral Hepatitis

Chronic hepatitis C virus (HCV) infection is characterized by increased proportion of CD4+CD8+ double positive (DP) T cells, but their role in this infection is unclear. In chronic hepatitis C, immune responses to HCV become functionally exhausted, w

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::98979ce9bc0e9d683c77d8daffa92ec6
http://europepmc.org/articles/PMC6850126

Zobrazit plný text záznamu

Plný text ve formátu HTML

Effect of comedication on ombitasvir/paritaprevir/ritonavir $\pm$ dasabuvir $\pm$ ribavirin therapy in chronic hepatitis C : a real-world study

Publikováno v: Clinical and Experimental Hepatology

Aim of the study This multicentre study aimed to examine the actual risk for drug-drug interactions in a cohort of Polish patients, and their impact on antiviral therapy. Material and methods Concomitant medications were analyzed in hepatitis C virus

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::12a4fa378cddeb853f524c9768b172c5
https://ruj.uj.edu.pl/xmlui/handle/item/256155

Zobrazit plný text záznamu

Real-world effectiveness and safety of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in hepatitis C: AMBER study

Publikováno v: Alimentary Pharmacology & Therapeutics. 44:946-956

SummaryBackground Virologic and safety outcomes of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin (OBV/PTV/r ± DSV ± RBV) therapy have shown high sustained virologic response (SVR) rates and good tolerability in most patient population

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b2aea8bdffa805ff8e3ab700aeb01977
https://doi.org/10.1111/apt.13790

Zobrazit plný text záznamu

Plný text ve formátu HTML

Durability of virologic response, risk of de novo hepatocellular carcinoma, liver function and stiffness 2 years after treatment with ombitasvir/paritaprevir/ritonavir±dasabuvir±ribavirin in the AMBER, real-world experience study

Autor: Kornelia Karwowska, E. Tuchendler, K. Simon, Katarzyna Fleischer-Stępniewska, Ewa Karpińska, Jolanta Białkowska, Dorota Zarębska-Michaluk, Mariusz Łucejko, Anna Piekarska, Krzysztof Tomasiewicz, Hanna Berak, Robert Flisiak, Olga Tronina, Aleksander Garlicki, Ewa Janczewska, Khalil Nazzal, Beata Bolewska

We followed for 2 years patients treated with direct-acting agents (DAA) to assess long-term durability of virologic response, improvement of liver function, reduction in liver stiffness (LS) and risk of hepatocellular carcinoma (HCC). The study incl

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d1e95f421f1100f9185a44334f178589
https://ruj.uj.edu.pl/xmlui/handle/item/143548

Zobrazit plný text záznamu

Influence of hepatic impairment on pharmacokinetics of the human GLP‐1 analogue, liraglutide

Autor: Paweł Jagielski, Anne Flint, Khalil Nazzal, Charlotte Hindsberger, Milan Zdravkovic

Publikováno v: British Journal of Clinical Pharmacology

WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • Liraglutide is a novel human GLP-1 analogue approved for treatment of type 2 diabetes mellitus. Since there is a high prevalence of co-morbid hepatic impairment in this population it is of clinical importa

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3cffd0a2b2e5f5fa5a1756d3b93f1cd2
https://doi.org/10.1111/j.1365-2125.2010.03762.x

Zobrazit plný text záznamu

Predictors of Fast Response to Ombitasvir/Paritaprevir/Ritonavir ± Dasabuvir ± Ribavirin in Real Life Amber Study in Genotype 1 and 4 HCV Infected Patients as a Rationale for Shortening of Treatment

Publikováno v: ResearcherID
Web of Science

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::02ba85858ec01efcbf0dd440a81fdd9c
https://doi.org/10.1016/s0168-8278(16)01592-0

Zobrazit plný text záznamu

[Pegylated interferon-alfa 2a with ribavirin in chronic viral hepatitis C (final report)]

Autor: Jacek, Juszczyk, Barbara, Baka-Cwierz, Marek, Beniowski, Hanna, Berak, Beata, Bolewska, Anna, Boroń-Kaczmarska, Janusz, Cianciara, Andrzej, Cieśla, Andrzej, Dziambor, Jacek, Gasiorowski, Andrzej, Gietka, Ewa, Gliwińska, Andrzej, Gładysz, Zbigniew, Gonciarz, Waldemar, Halota, Andrzej, Horban, Małgorzata, Inglot, Urszula, Janas-Skulina, Ewa, Janczewska-Kazek, Jolanta, Jaskowska, Krzysztof, Jurczyk, Brygida, Knysz, Wiesław, Kryczka, Jan, Kuydowicz, Elzbieta A, Lakomy, Beata, Logiewa-Bazger, Anna, Lyczak, Tomasz, Mach, Włodzimierz, Mazur, Zofia, Michalska, Roma, Modrzewska, Khalil, Nazzal, Paweł, Pabjan, Anna, Piekarska, Paweł, Piszko, Katarzyna, Sikorska, Katarzyna, Szamotulska, Magdalena, Sliwińska, Katarzyna, Swietek, Krzysztof, Tomasiewicz, Ewa, Topczewska-Staubach, Hanna, Trocha, Marek, Wasilewski, Marta, Wawrzynowicz-Syczewska, Witold, Wrodycki, Dorota, Zarebska-Michaluk, Małgorzata, Zejc-Bajsarowicz

Publikováno v: Przeglad epidemiologiczny. 59(3)

We evaluated the efficacy and safety of peginterferon alfa-2a [40KD] (Peg-IFNalpha-2a) plus ribavirin in patients with chronic hepatitis C in an open-label programme in a routine clinical setting in Poland. Patients received Peg-IFNalpha-2a 180mg/wee

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::febdf6f25a2920c57ed2d3ce9569f640
https://pubmed.ncbi.nlm.nih.gov/16433307

Zobrazit plný text záznamu

[Lamivudine in patients with chronic HBV infection and therapeutic difficulties]

Autor: Janusz, Cianciara, Aneta, Cybula, Khalil, Nazzal, Joanna, Jabłońska, Teresa, Łoch, Grazyna, Walencik

Publikováno v: Polskie Archiwum Medycyny Wewnetrznej. 107(1)

The primary objective of this study was to determine the efficacy and safety of lamivudine (LAM) therapy in patients with chronic HBV infection and contraindications to IFN therapy, nonresponders to IFN and patients with advanced liver fibrosis.In th

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::98c4a9e4e7a6a391855950b2e0bd1b35
https://pubmed.ncbi.nlm.nih.gov/12046342

Zobrazit plný text záznamu

A multi-center open study to determine the effect of lamivudine on HBV DNA clearance and to assess the safety of the regimen in patients with chronic hepatitis B infection

Autor: Włodzimierz, Mazur, Franciszek, Król, Janusz, Cianciara, Khalil, Nazzal, Andrzej, Gładysz, Jacek, Juszczyk, Beata, Bolewska, Jacek, Adamek, Barbara, Czajka, Katarzyna, Swietek, Wiesław, Kryczka, Zbigniew, Gonciarz

Publikováno v: Medical science monitor : international medical journal of experimental and clinical research. 8(4)

Patients with on-going HBV viral replication often present with clinical features of active chronic hepatitis. Until the recent introduction of nucleoside analogues, interferon-alpha was the only approved drug for these patients. One of the former dr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::fac80edd8d3030af673ffd8158ee2c13
https://pubmed.ncbi.nlm.nih.gov/11951067

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání